The definition of indications for allogeneic SCT in children with high-risk (HR) ALL in the first remission or after the first or subsequent relapse depends on biological features, response to treatment and survival after chemotherapy alone. As the results of frontline and relapse protocols are improving over time, there is a strong need for prospective SCT trials, ensuring a well-standardized procedure regarding all relevant components that are potentially responsible for heterogeneity in post-SCT outcome. Therefore, in 2003, the ALL-BFM and the ALL-REZ BFM Study Group initiated a prospective, international, multicenter trial (ALL- SCT-BFM 2003). This trial will now be extended to a larger consortium, trial ALL-SCT-BFM-international (ALL-SCT-BFMi). Strict rules define HLA-typing, donor selection, conditioning regimen, GvHD prophylaxis and therapy as well as standards of supportive care to reduce treatmentrelated mortality and establish an early GVL effect. Moreover, comprehensive and closely reviewed documentation and serious adverse event reporting shall ensure high study quality. Case-by-case discussions of any fatal or critical course during annual meetings will improve the culture of failure management and lead to modifications of guidelines of supportive care. Finally, the results of these prospective trials will determine the current potential of the different SCT procedures in HR or relapsed childhood ALL.
Introduction
Majority of patients with childhood ALL have a rather good prognosis. 1, 2 As allogeneic SCT is still a therapeutic option that can cause acute mortality and long-term morbidity in 10-30% of all patients, indications in CR1 are rare, but also in CR2, not all patients need to be transplanted, as outcome by chemotherapy alone is fairly good in some well-defined subgroups. [3] [4] [5] Consequently, all patients with an indication for SCT should nowadays be treated within prospective clinical trials to ensure best clinical practice and to acquire valid outcome data. 6 In 2003, the ALL-BFM Study Group initiated a prospective, international, multicenter trial (ALL-SCT-BFM 2003) enrolling all pediatric patients in Germany, Austria and Switzerland with ALL in first, second or subsequent remission, and having an indication for SCT according to the frontline/relapse chemotherapy protocols. Besides the standardization of SCT in childhood ALL, the main objective of this still open trial is to evaluate whether an SCT from an HLA-identical matched sibling donor (MSD) is equivalent to an SCT from a very well-matched unrelated donor (MD). Further goals are to evaluate the efficacy of SCT from HLA-MMD (mismatched donors) compared with SCT from MD/MSD, as well as the incidence of acute and chronic GvHD after SCT. Since 2007, an extension to more recruiting nations and SCT units has been achieved by initiating and opening the trial ALL-SCT-BFM-international (ALL-SCT-BFMi).
Prognostic factors and SCT indications
SCT indications have to be defined prospectively and must be re-evaluated and reconfirmed in intervals dependent on modifications and improvements of the chemotherapeutical approaches of the frontline and relapse protocols. Some risk factors for a dismal prognosis in childhood ALL are known even at diagnosis of ALL/relapse of ALL (for example, cytogenetic characteristics, time and site of relapse). 7 Additionally, response to induction treatment measured by morphology and/or detection of minimal residual disease has a strong predictive value and defines SCT indications (for example, non-remission on day 33 (NRd33): X5% blasts in BM after induction therapy) or modifies SCT indications (for example, for MD-SCT indication in S2 patients only if minimal residual disease is X10
À3 after the second induction block (F2) in relapse treatment). Further details are shown in Table 1 for ALL (CR1) and Table 2 for ALL (XCR2).
Donor selection and stem cell source
The outcome of SCT is highly dependent on the availability of an HLA-compatible donor. 8 So far, an MSD has been the gold standard for the outcome of SCT in all indications. 9 As the availability of an MSD is ensured only in about 15-20% of all patients, one major goal of our trial is to evaluate if a very wellmatched unrelated donor may be equivalent to an MSD nowadays. Therefore, besides HLA-high-resolution typing including the HLA-C locus, we defined an algorithm to choose the best donor in case of having identified more than one: one mismatch on antigen level is inferior to an allele mismatch, the subsequent priorities are the matching of the CMV serostatus, then sex and age of donor and recipient. Details for donor definitions are shown in Table 3 .
Preferably, unmanipulated BM was chosen as the stem cell source from MD in ALL-SCT-BFM 2003, as it is shown that the use of PBSC is associated with a higher incidence of chronic GvHD. 10 T-cell depletion is performed only in an MMD situation. Initially, the trial committee did not recommend cord blood from unrelated donors, as data published so far were not prospectively evaluated. 11 As unrelated donor cord blood has become more widely used . MRD-MR: any MRD positivity after 4 and 12 weeks induction treatment, but o10 À3 at week 12 (TP2). MRD-HR: MRDX10 À3 at week 12 (TP2). a PPR+ pro-B ALL or T-ALL and/or M3 d15 and/or WBC4100 000/ml. b PPR+ none of the above criteria. Time point of relapse: very early, o18 months after primary diagnosis; early, X18 months after primary diagnosis and o 6 months after cessation of frontline therapy; late, X6 months after cessation of frontline therapy. a MRD detected after the second induction block; if no MRD is available, MSD-SCT is indicated; MD-SCT indication is dependent on conventional clinical risk factors.
Table 3
Definition of donor groups regarding HLA-matching and relationship nowadays, it is an acceptable alternative for patients lacking a suitable donor in ALL-SCT-BFMi.
Conditioning regimen
The choice of the conditioning regimen has a significant impact on survival after SCT. It was shown retrospectively that conditioning with TBI/VP16 was comparable with TBI/ARA-C/MEL (melphalan). [12] [13] [14] BU/CY/MEL as an irradiation-free conditioning was inferior because of higher incidence of relapses as well as treatment-related mortality.
15 Therefore, the current standard backbone for MD consists of fractionated TBI (12 Gy) and etoposide. 16 Patients in whom TBI is not applicable because of young age or having already received high irradiation doses, TBI is substituted by i.v. BU. For MMD, in addition to TBI or BU, fludarabine and CY are given as a highly lymphocytotoxic drug combination.
In patients with t(4;11), so far the benefit of allogeneic SCT could not be clearly demonstrated by retrospective analysis. 17 As outcome after treatment by chemotherapy only is also not satisfying, it was decided to choose a particular conditioning regimen consisting of BU, CY and MEL, as it was shown to be effective in patients with juvenile myelomonocytic leukemia and AML. 18 
GvHD prophylaxis and therapy
Heterogeneities in GvHD prophylaxis and therapy are a structural weakness of retrospectively analyzed patient cohorts. 19, 20 Therefore, it is a major goal of our trial to apply a well-standardized and risk-adapted GvHD prophylaxis and therapy. In MSD, GvHD prophylaxis consists of CsA; in MD, additional short MTX and ATG-F are administered. In MMD, CD34-positive selection or CD3/CD19 depletion is performed and no pharmacological immunosuppression is applied. 21, 22 Supportive care
Standards of supportive care are important to avoid and anticipate severe clinical problems. Viral and fungal infections are known to be one major reason for treatment-related mortality post SCT (outpatients and patients suffering from GvHD). 23, 24 Therefore, adenovirus, CMV and EBV must be monitored in the peripheral blood by serial PCR analysis till sufficient reconstitution of the immune system is evident (T lymphocytes 4300/ml PB). In case of increasing viremia, a preemptive treatment strategy is strongly recommended and defined. 25 
Documentation and SAE reporting
Quality of documentation is one of the secondary objectives. Complete prospective data sets are essential for final analysis, but are also known to improve clinical management in the SCT units by reflecting patients' histories during the process of documentation. SAE (serious adverse event) reporting is implemented as a major tool to recognize systematic problems regarding the protocol or single SCT units as early as possible. In yearly meetings, the study committee discusses all these individual SAEs in detail to improve the guidelines of supportive care during the running protocol. This culture of failure management is essential to minimize treatment-related mortality as much as possible.
Future perspectives
As the prospective trial ALL-SCT-BFM 2003 is still ongoing, interim results regarding the outcome are not to be presented. However, it can be mentioned that since the early beginning of the trial, the rate of treatment-related mortality seems to decrease. This is a very well-known phenomenon: if patients are treated within a prospective trial, they are monitored closely and treatment quality improved.
The ALL-SCT-BFMi trial, which is now open, enables worldwide recruitment of transplanted childhood ALL patients from all interested nations, groups and/or SCT units. In addition to the regular 'participating membership,' it also allows the status of a 'registering membership' for those who may not change their current SCT procedures now but would want to share their data prospectively and participate in the trial committee and attend its annual meetings.
Results from both trials will be a very stable basis for the subsequent ALL-SCT trial, in which identification of patients at the highest risk of relapse after SCT and implementation of controlled modifications of the SCT procedure for those patients will be the next major goals.
